CY1109347T1 - Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης - Google Patents
Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονηςInfo
- Publication number
- CY1109347T1 CY1109347T1 CY20091100900T CY091100900T CY1109347T1 CY 1109347 T1 CY1109347 T1 CY 1109347T1 CY 20091100900 T CY20091100900 T CY 20091100900T CY 091100900 T CY091100900 T CY 091100900T CY 1109347 T1 CY1109347 T1 CY 1109347T1
- Authority
- CY
- Cyprus
- Prior art keywords
- signal transducer
- combination consisting
- combination
- derivative
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αφορά έναν συνδυασμό που αποτελείται από (α) έναν αναστολέα μεταλλαγής σήματος που επιλέγεται από έναν αναστολέα κινάσης τυροσίνης υποδοχέα PDGF (παράγοντας ανάπτυξης που προέρχεται από τα αιμοπετάλια) και ένα ενεργό συστατικό στοιχείο που μειώνει τη δραστηριότητα του επιδερμικού αυξητικού παράγοντα (EGF) ένα παράγωγο εποθιλόνης του τύπου (I) στην οποία ένωση το Α δηλώνει το Ο ή το NRn όπου το Rn είναι υδρογόνο ή κάτω αλκύλιο, το R είναι υδρογόνο ή κάτω αλκύλιο, και το Ζ είναι Ο ή ένας δεσμός και προαιρετικά τουλάχιστον έναν φαρμακευτικά αποδεκτό φορέα για ταυτόχρονη, ξεχωριστή ή συνεπαγόμενη χρήση, πιο συγκεκριμένα, για την καθυστέρηση της εξέλιξης μιας πολλαπλασιαστικής ασθένειας ή για τη θεραπεία αυτής, μια φαρμακευτική ένωση που περιλαμβάνει τον εν λόγω συνδυασμό, η χρήση του εν λόγω συνδυασμού για την παρασκευή ενός φαρμάκου για την καθυστέρηση της εξέλιξης ή για τη θεραπεία μιας πολλαπλασιαστικής ασθένειας, ένα εμπορικό πακέτο ή προϊόν που αποτελείται από τον εν λόγω συνδυασμό ως συνδυασμένο παρασκεύασμα για ταυτόχρονη, ξεχωριστή ή συνεπαγόμενη χρήση, και τον εν λόγω συνδυασμό για χρήση σε μια μέθοδο θεραπείας ενός θερμόαιμου θηλαστικού, ιδιαίτερα του ανθρώπου.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0104840.4A GB0104840D0 (en) | 2001-02-27 | 2001-02-27 | Use of organic compounds |
US33904001P | 2001-10-30 | 2001-10-30 | |
EP02744903A EP1385522B1 (en) | 2001-02-27 | 2002-02-26 | Combination comprising a signal transduction inhibitor and an epothilone derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109347T1 true CY1109347T1 (el) | 2014-07-02 |
Family
ID=26245767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100900T CY1109347T1 (el) | 2001-02-27 | 2009-08-28 | Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης |
Country Status (23)
Country | Link |
---|---|
US (1) | US7723339B2 (el) |
EP (1) | EP1385522B1 (el) |
JP (1) | JP4499359B2 (el) |
KR (1) | KR100848197B1 (el) |
CN (1) | CN1511036B (el) |
AT (1) | ATE434438T1 (el) |
AU (1) | AU2002308218B2 (el) |
BR (1) | BR0207649A (el) |
CA (1) | CA2439268C (el) |
CY (1) | CY1109347T1 (el) |
DE (1) | DE60232719D1 (el) |
DK (1) | DK1385522T3 (el) |
ES (1) | ES2326264T3 (el) |
HK (1) | HK1062266A1 (el) |
IL (2) | IL157466A0 (el) |
MX (1) | MXPA03007729A (el) |
NO (1) | NO325416B1 (el) |
NZ (1) | NZ527764A (el) |
PL (1) | PL207197B1 (el) |
PT (1) | PT1385522E (el) |
RU (1) | RU2313345C2 (el) |
SK (1) | SK287489B6 (el) |
WO (1) | WO2002067941A2 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2273083C (en) * | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP1383490B1 (en) | 2001-03-14 | 2012-04-25 | Bristol-Myers Squibb Company | Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases |
EP1704863A3 (en) * | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent |
PL392652A1 (pl) * | 2001-05-16 | 2010-12-06 | Novartis Ag | Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację |
WO2003037897A2 (en) * | 2001-10-29 | 2003-05-08 | Novartis Ag | Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases |
ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
TW225528B (el) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
CA2224435C (en) * | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
DK1367057T3 (da) | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
AU5036999A (en) * | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
IL144370A0 (en) * | 1999-02-11 | 2002-05-23 | Schering Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
-
2002
- 2002-02-26 US US10/469,367 patent/US7723339B2/en not_active Expired - Fee Related
- 2002-02-26 AT AT02744903T patent/ATE434438T1/de active
- 2002-02-26 NZ NZ527764A patent/NZ527764A/en not_active IP Right Cessation
- 2002-02-26 BR BR0207649-7A patent/BR0207649A/pt not_active Application Discontinuation
- 2002-02-26 EP EP02744903A patent/EP1385522B1/en not_active Expired - Lifetime
- 2002-02-26 ES ES02744903T patent/ES2326264T3/es not_active Expired - Lifetime
- 2002-02-26 CN CN028056086A patent/CN1511036B/zh not_active Expired - Fee Related
- 2002-02-26 SK SK1071-2003A patent/SK287489B6/sk not_active IP Right Cessation
- 2002-02-26 CA CA002439268A patent/CA2439268C/en not_active Expired - Fee Related
- 2002-02-26 IL IL15746602A patent/IL157466A0/xx unknown
- 2002-02-26 RU RU2003127392/15A patent/RU2313345C2/ru not_active IP Right Cessation
- 2002-02-26 MX MXPA03007729A patent/MXPA03007729A/es active IP Right Grant
- 2002-02-26 DK DK02744903T patent/DK1385522T3/da active
- 2002-02-26 PL PL363288A patent/PL207197B1/pl not_active IP Right Cessation
- 2002-02-26 DE DE60232719T patent/DE60232719D1/de not_active Expired - Lifetime
- 2002-02-26 KR KR1020037011205A patent/KR100848197B1/ko not_active IP Right Cessation
- 2002-02-26 AU AU2002308218A patent/AU2002308218B2/en not_active Ceased
- 2002-02-26 PT PT02744903T patent/PT1385522E/pt unknown
- 2002-02-26 JP JP2002567308A patent/JP4499359B2/ja not_active Expired - Fee Related
- 2002-02-26 WO PCT/EP2002/002049 patent/WO2002067941A2/en active IP Right Grant
-
2003
- 2003-08-18 IL IL157466A patent/IL157466A/en not_active IP Right Cessation
- 2003-08-25 NO NO20033769A patent/NO325416B1/no not_active IP Right Cessation
-
2004
- 2004-07-15 HK HK04105220.7A patent/HK1062266A1/xx not_active IP Right Cessation
-
2009
- 2009-08-28 CY CY20091100900T patent/CY1109347T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109347T1 (el) | Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης | |
NO20044093L (no) | N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin belagte stenter | |
NO20076323L (no) | Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat | |
IL176070A0 (en) | COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF | |
BR0314112A (pt) | Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia | |
CY2008010I2 (el) | Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες | |
CY1110385T1 (el) | Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης | |
NO20041582L (no) | Antistoffinhibitorer av GDF-8 og anvendelse derav | |
ATE321556T1 (de) | Behandlung gastrointestinaler stroma-tumoren | |
NO20045434L (no) | En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom | |
DK1326853T3 (da) | Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7 | |
EE200300041A (et) | Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid | |
DE60308337D1 (de) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten | |
DE10204822B8 (de) | Eingabe-/Ausgabeleitungs-Abtastverstärker eines Halbleiterspeicherbauelementes | |
DE60332862D1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
NO20023956D0 (no) | Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser | |
NO20034124D0 (no) | Sammensetning av et taxan og en cyclinavhengig kinaseinhibitor | |
ATE348615T1 (de) | 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit | |
ATE298333T1 (de) | Synthese von 4-(piperidyl) (2-pyridyl)methanon- (e)-o-methyloxim und seinen salzen | |
EE200000638A (et) | 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm | |
DK1353906T3 (da) | Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf | |
SI1436282T1 (en) | Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts |